

MEDIA RELEASE: Sydney, Australia, February 7, 2011.

PHEBRA INJECTS \$16 MILLION INTO NEW MANUFACTURING PLANT



The Australian pharmaceutical company, Phebra, announced today that it will invest \$16 million into a new manufacturing plant in Sydney's inner North West.

The Chief Executive Officer of Phebra, Dr Mal Eutick, said the new plant would lead to the creation of extra jobs through expanded research and development and production capacity and associated flow-on investments into the local pharmaceutical industry.

"We are pleased to announce the acquisition of our new headquarters at Lane Cove West," Dr Eutick said today.

"The new facility is approximately double the size of our last home at Lane Cove and as a result, will assist us in continuing our sustained and strong growth across both local and overseas markets."

Phebra is an Australian-based specialty pharmaceutical company which develops, manufactures and markets critical medicines in Australia, New Zealand, Asia, Canada and parts of Europe.



The company's critical medicines cover a range of pharmaceuticals in important disease areas such as cystic fibrosis, antidotes, diagnostics, oncology and pain. Phebra's range of sterile injections, which are used throughout the Australian hospital system, are currently manufactured at its Lane Cove facility.

Dr Eutick said the new plant will house more staff and be used for drug development and manufacturing.

"A key feature of the plant will be a new, multi-purpose sterile plant, of at least 1,000 square metres," he explained.

"This added capacity will allow us to boost our current research and development programs for the development of medicines and supply for clinical trials."

Phebra will begin construction of the new plant early in 2011.

At Phebra, we create critical medicines that save and improve lives.

Media contact:
The Premier Communications Group
+61 2 92473337
info@premiercomms.com.au